Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study / Andre, F; Neven, P; Musolino, A; Latini, L; Campone, M; Cortes, J; Barrios, Ch; Squires, M; Zhang, Y; Deudon, S; Yovine, Aj; Blackwell, Kl. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:15(2013).

Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study

Musolino, A;
2013-01-01

2013
Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study / Andre, F; Neven, P; Musolino, A; Latini, L; Campone, M; Cortes, J; Barrios, Ch; Squires, M; Zhang, Y; Deudon, S; Yovine, Aj; Blackwell, Kl. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:15(2013).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2875594
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact